MAM14 Immunotherapy Protocol: The Dream of Ophthalmologist, Became at Your Door. This Protocol Can Treat Autoimmune Uveitis.

Authors

  • Saleh A. Alharbi
  • Ali S. Alharbi
  • Sami Alrabea

Keywords:

MAM14 immunotherapy, uveitis, steroid, lymphocyte infiltration, cornea degradation.

Abstract

Uveitis doesn't have to involve a lifelong treatment course (C Stephen Foster). In this article we replaced conventional steroid and other immunosuppressant treatment by safe and new immunomodulation called MAM14 immunotherapy protocol, designed to treat uveitis. Our objective is to replace steroid and other immunosuppresant with safe effective immunomodulation method.   As a first trial to study this protocol, we choose one hundred twelve female uveitis patients called: experimental group; their age range between 13-15 years old, treated by MAM14 immunotherapy, which is briefly, paternal stressed allogeneic lymphocyte vaccination given subcutaneously to their daughters. Compared to 120 female control group uveitis patients age range between 12-16 years old received routine prednisone eye drops (Pred Forte). Results for the Slit lamp microscope showed that the experimental group demonstrates remarkable improvement duration of treatment four to nine months. Improvement lasted for ten years. No side effect noted during experiment and until this writing compared to control. Pachymeter showed no degradation of cornea and slit lamp showed no lymphocyte infiltration.

 On the other hand, symptoms and signs of control group patients is up and down. Lymphocyte infiltration is variable and degradation of cornea is prominent. As a conclusion we can say that it is time for autoimmune uveitis attack to be controlled immunologically.

References

[1] O. M. Durrani, C. A. Meads, P. I. Murray. (2004). “Uveitis: a potentially blinding disease.” Ophthalmologica. 218, pp. 223–236.
[2] R. B. Nussenblatt. (1990). “The natural history of uveitis.” International Ophthalmology. 14, pp. 303–308.
[3] J. ten Doesschate. (1982). “Causes of blindness in The Netherlands.” Doc. Ophthalmology. 52, pp. 279–285.
[4] National Advisory Eye Council. (1983). “Vision Research. A National Plan 1983-1987.” National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services. p. 13.
[5] O. M. Durrani, N. N. Tehrani, J. E. Marr, P. Moradi, P. Stavrou, P. I. Murray. (2004). “Degree, duration, and causes of visual loss in uveitis.” British Journal of Ophthalmology. 88, pp. 1159–1162.
[6] E. Bloch-Michel, R. B. Nussenblatt. (1987). “International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease.” American Journal of Ophthalmology. 103, pp. 234–235.
[7] D. A. Jabs, R. B. Nussenblatt, J. T. Rosenbaum. (2005). “Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.” American Journal of Ophthalmology. 140, pp. 509–516
[8] A. Rothova, M. S. Suttorp-van Schulten, W. Frits Treffers, A. Kijlstra. (1996) “Causes and frequency of blindness in patients with intraocular inflammatory disease.” British Journal of Ophthalmology. 80, pp. 332–336.
[9] D. E. Henderly, A. J. Genstler, R. E. Smith, N. A. Rao. (1987) “Changing patterns of uveitis.” American Journal of Ophthalmology. 103, pp. 131–136.
[10] C. A. McCannel, G. N. Holland, C. J. Helm, P. J. Cornell, J. V. Winston, T. G. Rimmer. (1996). “UCLA Community-Based Uveitis Study Group Causes of uveitis in the general practice of ophthalmology.” American Journal of Ophthalmology. 121, pp. 35–46.
[11] A. Mercanti, B. Parolini, A. Bonora, Q. Lequaglie, L. Tomazzoli. (2001). “Epidemiology of endogenous uveitis in north-eastern Italy. Analysis of 655 new cases.” Acta Ophthalmology Scand. 79, pp. 64–68.
[12] P. T. Merrill, J. Kim, T. A. Cox, C. C. Betor, R. M. McCallum, G. J. Jaffe. (1997). “Uveitis in the southeastern United States.” Current Eye Research. 16, pp. 865–874.
[13] J. Palmares, M. F. Coutinho, J. Castro-Correia. (1990) “Uveitis in northern Portugal.” Current Eye Research. 9(Suppl), pp. 31–34.
[14] E. S. Perkins, J. Folk. (1984). “Uveitis in London and Iowa.” Ophthalmologica. 189, pp. 36–40. [
[15] P. Pivetti-Pezzi, M. Accorinti, M. La Cava, R. A. Colabelli Gisoldi, M. A. Abdulaziz. (1996). “Endogenous uveitis: an analysis of 1,417 cases.” Ophthalmologica. 210, pp. 234–238.
[16] A. Rodriguez, M. Calonge, M. Pedroza-Seres, Y. A. Akova, E. M. Messmer, D. J. D’Amico, C. S. Foster. (1996). “Referral patterns of uveitis in a tertiary eye care center.” Arch Ophthalmology. 114, pp. 593–599.
[17] A. Rothova, H. J. Buitenhuis, C. Meenken, C. J. Brinkman, A. Linssen, C. Alberts, L. Luyendijk, A. Kijlstra. (1992). “Uveitis and systemic disease.” British Journal of Ophthalmology. 76, pp. 137–141.
[18] M. Santin, F. Badrinas, J. Mascaro, J. M. Nolla, O. Pujol, G. Roca, J. Valverde, J. Mana, F. Fernandez-Nogues. (1991) “Uveitis: an etiological study of 200 cases following a protocol.” Med Clin (Barc ). 96, pp. 641–644.
[19] R. L. Smit, G. S. Baarsma, J. de Vries. (1993). “Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital.” Intermatopma; Ophthalmology. 17, pp.71–76.
[20] V. T. Tran, C. Auer, Y. Guex-Crosier, N. Pittet, C. P. Herbort. (1994). “Epidemiological characteristics of uveitis in Switzerland.” International Ophthalmology. 18, pp. 293–298.
[21] C. S. Foster, A. T. Vitale. Diagnosis and Treatment of Uveitis. Philadelphia, PA: W. B. Saunders Company, 2002.
[22] D. A. Jabs, J. T. Rosenbaum, C. S. Foster, G. N. Holland, G. J. Jaffe, J. S. Louie, R. B. Nussenblatt, E. R. Stiehm, H. Tessler, R. N. Van Gelder, S. M. Whitcup, D. Yocum. (2000) “Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.” American Journal of Ophthalmology. 130, pp. 492–51323.
[23] R. B. Nussenblatt, S. M. Whitcup, A. G. Palestine. Uveitis. Fundamentals and Clinical Practice. St. Louis, MO: Mosby, 1996.
[24] Mark McCarty, Saleh A Alharbi. (2013). “Hypotheses.” 81, pp. 773-776.
[25] Saleh A Alharbi, Ali S Alharbi. (2015). “IgA Nephropathy improved by a new modality: MAM14 Immunotherapy: A case report in Kuwait.” (2015) ASRJETS. Volume 14, No. 1, pp. 23-27.
[26] T. Suzuki, Y. Kinoshita, M. Tachibana, et al. (2001). “Expression of sex steroid hormone receptors in human cornea.” Current Eye Research. 22, pp. 28–33.
[27] Eberhard Spoerl, Viktoria Zubaty, Frederik Raiskup?Wolf, and Lutz E. Pillunat. (November, 2007). “Oestrogen?induced changes in biomechanics in the cornea as a possible reason for keratectasia.” British Journal of Ophthalmology. 91(11), pp. 1547–1550.
[28] A. Boyum, J. Scand. “Isolation of mononuclear cells and granulocytes from human blood. (Paper IV).”
[29] A. Epstein. (2000). “ Keratoconus and related disorders.” (PDF) North Shore Contact Lens. Retrieved September 8, 2007.

Downloads

Published

2015-09-02

How to Cite

Alharbi, S. A., Alharbi, A. S., & Alrabea, S. (2015). MAM14 Immunotherapy Protocol: The Dream of Ophthalmologist, Became at Your Door. This Protocol Can Treat Autoimmune Uveitis. American Scientific Research Journal for Engineering, Technology, and Sciences, 14(1), 100–106. Retrieved from https://asrjetsjournal.org/index.php/American_Scientific_Journal/article/view/938